Kapoor Rinky, Shome Debraj
a Department of Cosmetic Dermatology & Facial Plastic Surgery, The Esthetic Clinics , Mumbai , India.
J Cosmet Laser Ther. 2018 Oct;20(6):369-379. doi: 10.1080/14764172.2018.1439965. Epub 2018 Feb 26.
Research has shown the efficacy of hair growth factors in hair regrowth. We describe the intradermal injections of a recombinant, bioengineered hair formulation, containing growth factors, into the scalp skin, for enhancement of hair regrowth and evaluate its efficacy.
The objective of this study was to assess the efficacy and safety of the hair growth factor formulation in reducing hair loss and enhancing hair growth.
This was an open-label, prospective, single-arm interventional pilot study in which 1000 patients were given intradermal injections of a hair formulation into the scalp skin. The formulation contains vascular endothelial growth factor, basic fibroblast growth factor, insulin-like growth factor, keratinocyte growth factor, thymosin β4, and copper tripeptide-1 suspended in a sterile injectable vehicle. Intradermal injections of this hair formulation were injected into the scalp once every 3 weeks for a total of eight such sessions. Hair pull test was performed before every session. Videomicroscopic and global images were taken at baseline, fourth session, eighth session, and 2 months after the completion of the eight sessions. Relevant safety assessments through physical examination, questionnaires, and appropriate laboratory examination were conducted throughout the study.
Significant reduction in hair fall was seen in 83% of the patients on hair pull test. Videomicroscopic image evaluation showed that most patients had a decrease in the number of vellus hairs, increase in number of terminal hairs, and increase in shaft diameter. Seventy-five percent of the patients believed that the hair injections were aiding the treatment of their hair loss, and it was also beneficial in post-hair transplant patients. At 1 year, a statistically significant increase in total hair count (P = 0.002) continued to be seen. Treatment was well tolerated.
Intradermal injections of this hair formulation may be a promising option for treating male as well as female patterns of hair loss.
研究表明毛发生长因子对毛发再生有效。我们描述了一种含有生长因子的重组生物工程毛发制剂皮内注射到头皮皮肤中以促进毛发再生，并评估其疗效。
本研究的目的是评估毛发生长因子制剂在减少脱发和促进头发生长方面的疗效和安全性。
这是一项开放标签、前瞻性、单臂干预性试点研究，1000名患者接受了该毛发制剂皮内注射到头皮皮肤中。该制剂含有血管内皮生长因子、碱性成纤维细胞生长因子、胰岛素样生长因子、角质形成细胞生长因子、胸腺素β4和铜三肽-1，悬浮于无菌可注射载体中。这种毛发制剂皮内注射每3周进行一次，共进行8次。每次注射前进行毛发牵拉试验。在基线、第4次注射、第8次注射以及8次注射完成后2个月拍摄视频显微镜图像和整体图像。在整个研究过程中通过体格检查、问卷调查和适当的实验室检查进行相关安全性评估。
在毛发牵拉试验中，83%的患者脱发明显减少。视频显微镜图像评估显示，大多数患者毳毛数量减少，终毛数量增加，毛干直径增加。75%的患者认为毛发注射有助于治疗脱发，对毛发移植术后患者也有益。在1年时，总毛发数量仍有统计学意义的显著增加（P = 0.002）。治疗耐受性良好。
这种毛发制剂皮内注射可能是治疗男性和女性脱发模式的一种有前景的选择。
Zotero 插件